ABSTRACT:Previously we observed that the antiestrogens tamoxifen and 4-hydroxytamoxifen (4OHT) induce CYP3A4 in primary human hepatocytes and activate human pregnane X receptor (PXR) in cell-based reporter assays. Given the complex cross-talk between nuclear receptors, tissue-specific expression of CYP3A4, and the potential for tamoxifen and 4OHT to interact with a myriad of receptors, this study was undertaken to gain mechanistic insights into the inductive effects of tamoxifen and 4OHT. First, we observed that transfection of the primary cultures of human hepatocytes with PXRspecific small interfering RNA reduced the PXR mRNA expression and the extent of CYP3A4 induction by tamoxifen and 4OHT by 50%. Second, in LS174T colon carcinoma cells, which were observed to have significantly lower PXR expression relative to human hepatocytes, neither tamoxifen nor 4OHT induced CYP3A4.Third, N-desmethyltamoxifen, which did not induce CYP3A4 in human hepatocytes, also did not activate PXR in LS174T cells. We then used cell-based reporter assay to evaluate the effects of other receptors such as glucocorticoid receptor GR␣ and estrogen receptor ER␣ on the transcriptional activation of PXR. The cotransfection of GR␣ in LS174T cells augmented PXR activation by tamoxifen and 4OHT. On the other hand, the presence of ER␣ inhibited PXR-mediated basal activation of CYP3A4 promoter, possibly via competing for common cofactors such as steroid receptor coactivator 1 and glucocorticoid receptor interacting protein 1. Collectively, our findings suggest that the CYP3A4 induction by tamoxifen and 4OHT is primarily mediated by PXR but the overall stoichiometry of other nuclear receptors and transcription cofactors also contributes to the extent of the inductive effect.Tamoxifen is a prototypical selective estrogen receptor modulator by virtue of its tissue-specific estrogen/antiestrogen properties. It is a clinically effective endocrine agent for the treatment and chemoprevention of breast cancer, and despite the advent of new antiestrogens, such as the aromatase inhibitors anastrazole and letrozole, it remains the drug of choice, especially in premenopausal women. Although tamoxifen is generally well tolerated, its clinical use is associated with several unresolved problems. These include interindividual variability in its pharmacokinetics and the resulting variability in its safety and efficacy profile and drug-drug interactions. Because the systemic elimination of tamoxifen primarily entails hepatic metabolism, intersubject variability in its metabolism is the principal cause of the overall variability in its pharmacokinetics. Tamoxifen is biotransformed to a larger number of metabolites, including N-desmethyltamoxifen (NDMT) and 4-hydroxytamoxifen (4OHT), which are further converted to 4-hydroxy-N-desmethyltamoxifen (endoxifen) (Borges et al., 2006). Whereas NDMT is a weak antiestrogen, 4OHT and endoxifen are considerably more potent antiestrogens than tamoxifen and may contribute to the overall therapeutic properties of the latter. A...